Immunotherapy to help grafts heal for people with limb loss
Treatments studied
Part of Immune system & allergy clinical trials.
This Phase 2 study tests an immune-targeting treatment to help a transplanted tissue “graft” integrate and heal better after limb loss. It may help by reducing problems with healing and rejection, but you must be able to complete frequent follow-up visits and testing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 18 and 65 years old
- Have a limb loss injury or amputation
- Be able and willing to give informed consent
- Be willing to travel to the study site for follow-up samples or send samples by overnight mail when needed
- Be able to do all required check-ins and treatments throughout the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial checks whether using heart-monitoring blood tests and biopsy results can help customize (optimize) immune-suppression medication soon after your transplant. It aims to keep the transplanted heart safe while avoiding over- or under-treatment.
This trial studies whether a transplant of tissue and blood vessels can improve function after limb amputations when prosthetic devices have not worked. It requires long-term medicines to prevent rejection, close follow-up, and intensive rehabilitation.
This trial tests replacing a missing or non-working lower arm/hand with a donated upper limb (transplant). It also uses a special immune treatment plan and bone marrow infusion to help the body accept the new limb, aiming to improve hand function and quality of life.
This study follows people who received a transplanted arm (or both arms) to learn from their ongoing care. You may be asked for small tissue samples (biopsies) and to continue an immunotherapy plan to help protect the transplant.
This study tests whether a drug called belatacept can safely help your body accept a new heart without rejecting it, and may reduce the need for other strong immune-suppressing medicines. If you are getting a heart transplant for the first time and have certain immune markers, this trial may be an option for you.
This trial studies whether belatacept can be used after a heart transplant to help protect kidney function over time. It focuses on people who already have (or are at risk for) worsening kidney function after transplant, while avoiding those with certain infections or rejection concerns.
Hear when a new Immunosuppression trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.